{"status": "ok", "totalResults": 77, "articles": [{"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://finance.yahoo.com/news/why-exact-sciences-corporation-stock-100000965.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/cuXO7YplZxOVKts6hNDIHw--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/motleyfool.com/e4f07b38fce926e7eda0457056f7069a", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences (NASDAQ: EXAS), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-m\u2026 [+2147 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Lilly, Teva, Pfizer & Others Await FDA Decisions in September", "description": "FDA grants approval to 34 new treatments this year so far.", "url": "https://finance.yahoo.com/news/lilly-teva-pfizer-others-await-125812067.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/EyZmh1klWYX.2_4cspNDgQ--~B/aD00MTM7dz02MjA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1c294b9de375a124a76eae049179f11e", "publishedAt": "2018-09-07T12:58:12Z", "content": "Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 d\u2026 [+4154 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status", "description": "Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.", "url": "https://finance.yahoo.com/news/pfizer-apos-skin-disease-drug-145702447.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/RcSGEOiRo4N.qL406x4Pog--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/zacks.com/df5ad064f24e5502d8d1fb68bd8dc90d", "publishedAt": "2018-09-06T14:57:02Z", "content": "Pfizer, Inc. PFE announced that it has received Breakthrough Therapy designation for its pipeline candidate, PF-06651600 from the FDA. The candidate is being developed for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, \u2026 [+3625 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://finance.yahoo.com/news/3-top-big-pharma-stocks-103000865.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/dMhJrTHQFTunhg6UyrJWsA--~B/aD0zODc7dz01ODA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/motleyfool.com/cac2a8c273ac939ed15d71ebb32efe02", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4838 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Cory Renauer)", "title": "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?", "description": "Here's what investors need to know about the disappointing results Sangamo announced recently.", "url": "https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493528%2Fbusinessman-in-shock-hands-on-head-laptop-surprise-investment-getty.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T12:48:00Z", "content": "An attempt to edit genetic flaws on the fly didn't work nearly as well as hoped for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), and the stock just took a dip. Is it time to cut and run? Before investors do any panic trading, there are a few things they need t\u2026 [+4435 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Nick Paul", "title": "After midphase flop, Pfizer taps Cytoo for help identifying DMD targets", "description": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data.", "url": "https://www.fiercebiotech.com/biotech/after-midphase-flop-pfizer-taps-cytoo-for-help-identifying-dmd-targets?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536316463/PfizerHQsignone.jpg/PfizerHQsignone.jpg?vOOHCcNj1UrRzDdMkYiDtHlm6yj70xsd", "publishedAt": "2018-09-07T10:35:16Z", "content": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance (PDF) comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data. Domagrozumab\u2019s in\u2026 [+1963 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Why Sangamo Therapeutics, Inc. Sank Again Today", "description": "Disappointing interim results for its gene-editing therapy continued to weigh on the biotech stock.", "url": "https://www.fool.com/investing/2018/09/06/why-sangamo-therapeutics-inc-sank-again-today.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493757%2Fdoctor-with-dna-and-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T21:00:00Z", "content": "What happened Shares of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech's interim update from a phase 1/2 clinical stu\u2026 [+2158 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Phil Taylor", "title": "Allogene raises another $120M for off-the-shelf CAR-T programs", "description": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer.", "url": "https://www.fiercebiotech.com/biotech/allogene-raises-120m-more-for-off-shelf-car-t-programs?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536237546/gold_piggy_bank.jpg/gold_piggy_bank.jpg?fAca5m0txEEIn7c85yHItb9bxKQSJq2F", "publishedAt": "2018-09-06T12:40:15Z", "content": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer. The biotech\u2014formed by Kite Pharma executives Arie Belldegrun and David Chang\u2014came out of ste\u2026 [+2415 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Arlene Weintraub, Contributor, Arlene Weintraub, Contributor https://www.forbes.com/sites/arleneweintraub/", "title": "Will Trump's Pharma Shaming Bring Down Drug Prices? Not Likely, Poll Says", "description": "President Trump promised \u201cvoluntary massive drops in prices\u201d from Big Pharma. Americans are skeptical.", "url": "https://www.forbes.com/sites/arleneweintraub/2018/09/06/will-trumps-pharma-shaming-bring-down-drug-prices-not-likely-poll-says/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F813697758%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T13:24:00Z", "content": "Share to facebook Share to twitter Share to linkedin High drug costs are a concern for voters in the 2018 midterm elections, a new poll reveals. (Source: Getty Royalty Free) In July, Pfizer put plans to raise the prices of some of its products on hold after P\u2026 [+6873 chars]"}, {"source": {"id": null, "name": "Acs.org"}, "author": "nobody@acs.org(\"\")", "title": "For District I director: Katherine L. Lee", "description": "", "url": "https://cen.acs.org/acs-news/elections/District-director-Katherine-L-Lee/96/i36?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+cen_latestnews+%28Chemical+%26+Engineering+News%3A+Latest+News%29", "urlToImage": "https://cen.acs.org/content/dam/cen/96/36/09636-acsnews4-lee.jpg", "publishedAt": "2018-09-07T13:15:22Z", "content": "Northeastern Section. Pfizer, Cambridge, Mass. Academic record: Yale University, B.S., summa cum laude, with distinction in chemistry, 1991; Massachusetts Institute of Technology, Ph.D., organic chemistry, 1996; University of Texas, Austin, postdoctoral fello\u2026 [+6268 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Joshua Cohen, Contributor, Joshua Cohen, Contributor https://www.forbes.com/sites/joshuacohen/", "title": "Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments", "description": "As the opioid crisis has unfolded concerns have grown about dependency and the potentially addictive nature of opioid-based pain treatments. Having satisfactory non-opioid treatment alternatives will need to be an integral part of effective pain management.", "url": "https://www.forbes.com/sites/joshuacohen/2018/09/06/tanezumabs-phase-3-results-a-promising-sign-for-non-opioid-pain-treatments/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F8850fc86753847019b09c48891d47021%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T12:11:00Z", "content": "Share to facebook Share to twitter Share to linkedin This Wednesday, March 29, 2017 photo shows a syringe involved in an experimental non-opioid pain medication trial at the Altoona Center for Clinical Research in Altoona, Pa. With about 2 million Americans a\u2026 [+11353 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Special Correspondent", "title": "Indices gain after six days of decline", "description": "Even as the rupee touched a new low on Thursday by falling below the 72-mark against the U.S. dollar for the first time ever, the benchmark equity ind", "url": "https://www.thehindu.com/business/indices-gain-after-six-days-of-decline/article24885253.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-06T16:45:45Z", "content": "Even as the rupee touched a new low on Thursday by falling below the 72-mark against the U.S. dollar for the first time ever, the benchmark equity indices gained ground after six consecutive days of losses. The 30-share Sensex gained 224.50 points, or 0.59%, \u2026 [+1405 chars]"}, {"source": {"id": null, "name": "Fiercepharma.com"}, "author": "Eric Sagonowsky", "title": "Ahead of Brexit, U.K.'s top insulin provider Novo Nordisk plans to double its stockpile", "description": "In advance of Brexit next year, Novo Nordisk plans a 4-month stockpile of critical insulins. The company is the largest insulin provider in the U.K.", "url": "https://www.fiercepharma.com/pharma/ahead-brexit-u-k-s-top-insulin-provider-novo-nordisk-more-than-doubles-its-stockpile?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercepharma/1536327250/BrexitconceptegaliStockGettyImagesplusGettyImages.jpg/BrexitconceptegaliStockGettyImagesplusGettyImages.jpg?H6vrkroxFNDkzDk4d2vyPuYIobYkmj6O", "publishedAt": "2018-09-07T13:35:17Z", "content": "One by one, drugmakers have disclosed plans to prepare for Brexit, which could leave British patients vulnerable to shipping delays and unable to access critical drugs. Novo Nordisk, the largest insulin supplier to the U.K., now says it\u2019ll more than double it\u2026 [+2459 chars]"}, {"source": {"id": null, "name": "Fiercepharma.com"}, "author": "Eric Palmer", "title": "Hospital-backed Civica Rx nabs Amgen vet as CEO and targets 14 drugs to knock off", "description": "A group of hospitals committed to manufacturing their own drugs to battle shortages and high costs now has a name, more support and a pharma manufacturing veteran to oversee the effort.", "url": "https://www.fiercepharma.com/manufacturing/hospital-supported-civica-rx-to-produce-14-drugs-are-chronic-shortage?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercepharma/1536241650/GettyImages-895696384.jpg/GettyImages-895696384.jpg?_0g8qRZNNplS44iztfBh49aN86_nts4W", "publishedAt": "2018-09-06T13:44:35Z", "content": "A group of hospitals committed to manufacturing their own drugs to battle shortages and high costs now has a name, more support and a pharma manufacturing veteran to oversee the effort. First announced in January as Project Rx, today the group said it will be\u2026 [+3149 chars]"}, {"source": {"id": null, "name": "Channelnewsasia.com"}, "author": null, "title": "Lilly's Elanco unit expects IPO to raise up to US$1.45 billion", "description": "Eli Lilly & Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to US$1.45 billion.", "url": "https://www.channelnewsasia.com/news/business/lilly-s-elanco-unit-expects-ipo-to-raise-up-to-us-1-45--billion-10690970", "urlToImage": "http://www.channelnewsasia.com/blob/10690968/55dc088d92d39a634c65f42c3c2e2c15/eli-lilly--amp--co-ceo-dave-ricks-poses-for-a-picture-at-the-j-p--morgan-healthcare-conference-in-san-francisco-1-data.jpg", "publishedAt": "2018-09-06T11:40:29Z", "content": "REUTERS: Eli Lilly &amp; Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to US$1.45 billion. The IPO is expected to be priced between US$20-US$23 per share. At the high end of the range\u2026 [+730 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "VCDeals", "title": "Goldman Sachs, Tencent Led $450M In Chinese E-Commerce Grocer", "description": "Welcome to Seeking Alpha\u2019s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday morn", "url": "https://seekingalpha.com/article/4205085-goldman-sachs-tencent-led-450m-chinese-e-commerce-grocer", "urlToImage": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "publishedAt": "2018-09-08T13:23:50Z", "content": "Welcome to Seeking Alpha\u2019s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Did we miss a notable deal? Let us know in the comments. Chinese produce: Goldman Sachs (NYSE\u2026 [+4672 chars]"}, {"source": {"id": null, "name": "Bostonherald.com"}, "author": "Lisa Schencker, By Lisa Schencker", "title": "Amid EpiPen shortage, Walgreens teams up with drug company to offer free alternative", "description": "Amid a shortage of EpiPens, Walgreens is partnering with a competing drugmaker to make it easier for consumers across the country to get its devices. Auvi-Qs \u2014 devices used to inject epinephrine to counter severe allergic reactions \u2014 are available for the fir\u2026", "url": "http://www.bostonherald.com/lifestyle/health/2018/09/amid_epipen_shortage_walgreens_teams_up_with_drug_company_to_offer_free", "urlToImage": "http://www.bostonherald.com/sites/default/files/styles/full/public/media/ap/2017/01/13/f96993dc0a7c4d29b097c194f6f57d7f.jpg?itok=foyYzSf0", "publishedAt": "2018-09-07T00:00:00Z", "content": "Amid a shortage of EpiPens, Walgreens is partnering with a competing drugmaker to make it easier for consumers across the country to get its devices. Auvi-Qs \u2014 devices used to inject epinephrine to counter severe allergic reactions \u2014 are available for the fir\u2026 [+3683 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Credit Suisse Joins Consensus To Prescribe Sarepta", "description": "The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...", "url": "https://finance.yahoo.com/news/credit-suisse-joins-consensus-prescribe-184754262.html", "urlToImage": null, "publishedAt": "2018-09-06T18:47:54Z", "content": "The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts Martin Auster, Mark Connolly and Tiago Fauth initiated \u2026 [+1778 chars]"}]}